Eli Lilly and Company (LLY) Stock Analysis
Is LLY a good investment?
Eli Lilly and Company (LLY) has a Plutrex AI rating of 87.0/100 as of July 10, 2026, indicating a Strong Buy consensus. The stock is halal-compliant per AAOIFI standards. Key strength: Dominant GLP-1 franchise controlling ~90% of the obesity drug market (per 'Two Drugmakers Own 90% of the Obesity Boom' headline), driving 55.5% revenue growth (516% above industry 9.0%) and 169.9% earnings growth (952% above industry 16.1%), with a trillion-dollar market opportunity still largely untapped per Wall Street analysis. Main concern: Near-term upside to analyst consensus remains modest at 5.7% ($1,216.95 to $1,286.54), and the P/E of 43.81x with P/B of 36.80x leaves minimal margin of safety if the 28.9% 5-year EPS growth trajectory disappoints — any material miss on GLP-1 volume, pricing, or pipeline execution would be severely punished at this valuation.
Investment Summary
Eli Lilly (LLY) at $1,216.95 remains one of the highest-quality compounders in global equity markets, anchored by a dominant GLP-1 franchise that controls ~90% of the obesity drug market alongside Novo Nordisk. The investment thesis is driven by exceptional fundamentals: gross margin of 82.8% (+18.3pp vs. industry 70.0%), operating margin of 49.4% (+15.8pp vs. industry 33.6%), net margin of 35.0% (+15.5pp vs. industry 19.5%), ROE of 107.6%, and $9.16B in annual free cash flow. The PEG ratio of 0.94 — 46.3% below the industry average of 1.75 — is the defining valuation signal: despite a P/E of 43.81x (38.9% premium to peers), investors are acquiring LLY's 28.9% 5-year EPS growth at a meaningful discount to what peers charge per unit of growth. Since the prior report 2 days ago, the stock has declined -1.5% from $1,235.56 to $1,216.95 while the analyst consensus target rose +1.0% from $1,273.38 to $1,286.54 — a double improvement in risk/reward that directly addresses the prior report's primary concern of compressed near-term upside. The upside to consensus has expanded from 3.1% to 5.7%, and the PEG improved from 0.98 to 0.94 (-4.1%). News sentiment of 93.7/100 (16 positive, 1 negative, 0 neutral) is near-perfect, with headlines confirming LLY's dominant market position ('Two Drugmakers Own 90% of the Obesity Boom'), institutional endorsement, and trillion-dollar market opportunity framing ('Wall Street Is Betting on Eli Lilly's GLP-1 Portfolio — It's Missing the $1 Tril...'). The combination of improved valuation, expanded upside to consensus, and near-perfect news sentiment warrants a modest upgrade from the prior 86.0 to 87.0.
Key Strengths
- Dominant GLP-1 franchise controlling ~90% of the obesity drug market (per 'Two Drugmakers Own 90% of the Obesity Boom' headline), driving 55.5% revenue growth (516% above industry 9.0%) and 169.9% earnings growth (952% above industry 16.1%), with a trillion-dollar market opportunity still largely untapped per Wall Street analysis
- Best-in-class profitability with gross margin 82.8% (+18.3pp vs. industry), operating margin 49.4% (+15.8pp vs. industry), net margin 35.0% (+15.5pp vs. industry), ROE 107.6%, and $9.16B annual FCF — metrics reflecting a structural competitive moat that is widening, not narrowing
- Growth-adjusted undervaluation with PEG of 0.94 (46.3% below industry average of 1.75x) and 5-year forward EPS CAGR of 28.9% (3.5x the industry rate of 8.3%), combined with improved risk/reward as stock declined -1.5% while analyst consensus target rose +1.0%, expanding upside from 3.1% to 5.7%
Key Concerns
- Near-term upside to analyst consensus remains modest at 5.7% ($1,216.95 to $1,286.54), and the P/E of 43.81x with P/B of 36.80x leaves minimal margin of safety if the 28.9% 5-year EPS growth trajectory disappoints — any material miss on GLP-1 volume, pricing, or pipeline execution would be severely punished at this valuation
- Debt-to-equity of 1.26x with cash of $5.28B relative to LLY's scale requires sustained strong cash generation; the capital-intensive GLP-1 manufacturing expansion and R&D pipeline investment mean any revenue growth deceleration could strain the balance sheet, as reflected in the financial health score of 45/100 (standalone)
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
LLY's fundamentals are elite across every profitability dimension. Gross margin of 82.8% reflects extraordinary pricing power — for every $1 of revenue, only $0.17 goes to cost of goods. Operating margin of 49.4% means nearly half of every revenue dollar becomes operating income after all R&D and SG&A spend, a level of operational leverage that is rare even among Big Pharma peers (industry average: 33.6%). Net margin of 35.0% confirms $0.35 of every revenue dollar is retained as profit (industry average: 19.5%). ROE of 107.6% — generating more than the entire equity base in annual profit — reflects world-class capital efficiency, though amplified by D/E of 1.26x. Revenue growth of 55.5% YoY (516% above industry average of 9.0%) and earnings growth of 169.9% (952% above industry average of 16.1%) demonstrate the explosive commercial success of the GLP-1 platform. Forward metrics show expected deceleration but remain exceptional: next-year EPS growth of 22.8% and 5-year EPS CAGR of 28.9% (3.5x the industry rate of 8.3%). The P/E of 43.81x appears elevated in isolation but the PEG of 0.94 (below the critical 1.0 threshold; 46.3% below industry average of 1.75x) confirms growth-adjusted undervaluation. FCF of $9.16B provides robust coverage of the 1.26x D/E leverage. Cash of $5.28B is modest relative to scale but FCF generation makes near-term financial distress a non-concern. Analyst consensus target of $1,286.54 implies 5.7% upside — improved from 3.1% two days ago.
News Sentiment
Eli Lilly is rewriting the rules of Big Pharma — and Wall Street can't stop talking about it. The Indianapolis-based drugmaker has engineered one of the most remarkable corporate transformations in recent memory, with its obesity and diabetes drugs triggering what analysts are calling a '$400 Billion Surge' that is 'Reshaping Big Pharma' (headline #1). At the heart of the story is Lilly's GLP-1 franchise — the class of drugs that includes Mounjaro and Zepbound — which has made the company one of just two drugmakers controlling roughly 90% of the booming obesity drug market, according to a recent analysis highlighting that 'Two Drugmakers Own 90% of the Obesity Boom' (headline #3). That duopoly position is so powerful that major healthcare ETFs like XLV are building core positions in both Lilly and rival Novo Nordisk simultaneously. But here's what's really catching investors' attention: Wall Street may actually be underestimating the opportunity. One analysis argues that investors are 'Missing the $1 Trillion' story embedded in Lilly's GLP-1 portfolio (headline #4) — suggesting the market hasn't fully priced in the long-term scale of the obesity treatment revolution. With the stock trading near $1,217 and carrying a price tag that has some wondering if it's too late to buy, analysts note that '$1,000 Invested Today Could' still generate meaningful returns given the company's 28.9% projected annual earnings growth over five years (headline #5). Adding intrigue: at over $1,200 per share, Lilly is increasingly being discussed as a potential stock split candidate (headline #2), which could broaden retail investor access and potentially catalyze additional demand.
Risk Assessment
Primary risk: GLP-1 market growth deceleration or competitive disruption (Novo Nordisk pipeline, emerging oral GLP-1 entrants) could compress the 28.9% 5-year EPS growth estimate, triggering multiple contraction from P/E 43.81x toward the industry average of 31.54x — a potential 28% downside from current levels. Secondary risk: Manufacturing capacity constraints limiting volume growth despite strong demand, as LLY has been supply-constrained in the GLP-1 ramp. Tertiary risk: Pricing pressure from potential Medicare drug price negotiations or lower-cost strategy (noted in news analysis) compressing the 82.8% gross margin. Mitigation: The PEG of 0.94 provides a growth-adjusted valuation cushion; $9.16B FCF covers debt service and R&D investment; the ~90% market share duopoly with Novo Nordisk creates structural barriers to entry; stop-loss at $1,095 (10.0% below entry midpoint of $1,202.50) limits downside. Position sizing at 3.0% reflects the compressed near-term upside to consensus (5.7%) and the elevated absolute valuation, while acknowledging the exceptional long-term compounding potential.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is LLY a halal stock?
Yes, Eli Lilly and Company (LLY) is halal-compliant per AAOIFI standards as of the latest quarterly review.
What is Plutrex's AI rating for LLY?
Eli Lilly and Company (LLY) has a Plutrex AI rating of 87.0/100 with a Strong Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is LLY a good investment?
According to Plutrex AI, LLY has a Strong Buy rating (87.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in LLY?
US stocks like LLY can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in LLY?
Plutrex AI identifies the main risks for LLY by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.